- Biologics License Application for sonelokimab submitted to the U.S. Food and Drug Administration for the treatment of adults and adolescents with moderate-to-severe hidradenitis suppurativa, marking an important step towards potential U.S. approval and commercialization
- Positive Week 16 results from the Phase 3 IZAR-1 trial in psoriatic arthritis reported, with all clinical endpoints met for sonelokimab 60 mg with induction
- Enrollment completed in the Phase 3 IZAR-2 trial in psoriatic arthritis, with initial topline results expected in Q1 2027 following the predefined unblinding protocol
- Phase 3 NOVA trial in palmoplantar pustulosis on track to start enrollment in November 2026
- MoonLake ended the third quarter with $498.5 million in cash, cash equivalents and short-term marketable debt securities and expects to have a cash runway to mid-2028; additionally, up to $400 million in non-dilutive funds remain available through its debt facility with Hercules Capital
ZUG, Switzerland, November 4, 2026 – MoonLake Immunotherapeutics (NASDAQ: MLTX) ("MoonLake" or the "Company"), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today provided a business update and reported third quarter 2026 financial results.
Third Quarter 2026 Business Highlights Hidradenitis suppurativa: On September 30, 2026, the Company submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA), seeking approval of sonelokimab (SLK) for the treatment of moderate-to-severe hidradenitis suppurativa (HS) in adults and pediatric patients 12 years of age and older. MoonLake expects to be notified by the FDA whether the BLA submission is accepted for review within approximately 60 days of submission, and to receive the planned review timeline within approximately 74 days of submission. The BLA is supported by data from the MIRA and VELA (incl. VELA-TEEN) clinical programs.
The Company expects to complete the VELA-TEEN clinical trial in the fourth quarter of 2026 and plans to submit final results for presentation at a scientific conference in the first quarter of 2027.
The Company continues to advance its preparations, including market access, medical affairs, patient engagement and commercial infrastructure for the potential launch of sonelokimab in the U.S., if approved.
Psoriatic arthritis:In August 2026, the Company announced positive results from an analysis of the Week 16 primary endpoint in the Phase 3 IZAR-1 trial in psoriatic arthritis (PsA), which met all clinical endpoints at Week 16 for 60 mg SLK. In the primary endpoint analysis, 42.1% of biologic-naïve patients treated with sonelokimab 60 mg with induction achieved an American College of Rheumatology 50 (ACR50) response at Week 16. In addition, sonelokimab demonstrated strong efficacy across multiple disease domains characteristic of PsA. Patients treated with sonelokimab demonstrated clinically meaningful improvements in patient-reported and physical outcomes. Consistent with the unblinding protocol defined with the FDA, topline disclosure at Week 16 included absolute response levels and endpoint outcomes for the sonelokimab 60 mg with induction arm. Comparative analyses versus placebo and detailed treatment arm data remain blinded until completion of the trial.
In September 2026, MoonLake completed enrollment for the Phase 3 IZAR-2 trial in PsA. The Company expects to announce initial topline results following a predefined unblinding protocol in the first quarter of 2027. In addition, MoonLake expects results of the P-OLARIS trial to become available in early 2027.
Palmoplantar pustulosis:The Company expects to commence enrollment in the Phase 3 NOVA trial as per plans in November 2026.
Third Quarter 2026 Financial Results Today, MoonLake also reported its financial results for the third quarter of 2026. As of September 30, 2026, MoonLake held cash, cash equivalents and short-term marketable debt securities of $498.5 million. The Company expects to have sufficient capital to fund its operating expenses and capital expenditure requirements to mid-2028. MoonLake’s debt facility with Hercules Capital provides up to $400 million in additional non-dilutive funds to support potential future funding needs. Research and development expenses were $68.9 million for the three months ended September 30, 2026, compared to $50.2 million for the three months ended June 30, 2026. The increase of $18.7 million is primarily related to accrued milestone license fees for a regulatory milestone associated with the expected acceptance of the Company's BLA submission. General and administrative expenses were $11.0 million for the three months ended September 30, 2026, compared to $11.4 million for the three months ended June 30, 2026.
Matthias Bodenstedt, Chief Financial Officer of MoonLake Immunotherapeutics, said: “This quarter reflects the strength of execution across MoonLake. With the BLA for sonelokimab in HS now submitted to the FDA, positive Week 16 results from the Phase 3 IZAR-1 trial and IZAR-2 fully enrolled, we are making important progress across both our regulatory and clinical priorities. At the same time, we believe our financial position and projected cash runway into mid-2028 position us well to prepare for the expected commercial launch of sonelokimab in the U.S. next year, and to continue advancing its broader potential across inflammatory diseases."
Important upcoming anticipated milestones for MoonLake:
- HS:
- Expected to receive a decision on BLA filing acceptance by the end of November 2026 and a Prescription Drug User Fee Act (PDUFA) goal date by mid December 2026
- Expected mid-cycle review in H1 2027
- Expected to conclude VELA-TEEN clinical trial in Q4 2026 and present final topline results at a scientific meeting in the first quarter of 2027
- Expected commercial launch in U.S. in H2 2027, if approved
- Expected to present year 1 VELA OLE data in H2 2027
- PPP: Expected to commence enrollment for the NOVA Phase 3 trial in November 2026
- PsA:
- IZAR-1: Expected to announce Week 52 topline results in Q2 2027
- IZAR-2: Expected to announce Week 16 topline results in Q1 2027 and Week 52 topline results in Q4 2027
- PsA/axial spondyloarthritis: Expected to announce results from the P-OLARIS trial in early 2027
-Ends-
About MoonLake Immunotherapeutics MoonLake Immunotherapeutics (“MoonLake” or the “Company”) is a clinical-stage biopharmaceutical company unlocking the potential of sonelokimab, a novel investigational Nanobody® for the treatment of inflammatory disease, to revolutionize outcomes for patients. Sonelokimab inhibits IL-17A and IL-17F by inhibiting the IL-17A/A, IL-17A/F, and IL-17F/F dimers that drive inflammation. The Company’s focus is on inflammatory diseases with a major unmet need, including hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis and palmoplantar pustulosis – conditions affecting millions of people worldwide with a large need for improved treatment options. MoonLake was founded in 2021 and is headquartered in Zug, Switzerland. Further information is available at https://moonlaketx.com.
About Nanobodies®Nanobodies® represent a new generation of antibody-derived targeted therapies. They consist of one or more domains based on the small antigen-binding variable regions of heavy-chain-only antibodies (VHH). Nanobodies® have a number of potential advantages over traditional antibodies, including their small size, enhanced tissue penetration, resistance to temperature changes, ease of manufacturing, and their ability to be designed into multivalent therapeutic molecules with bespoke target combinations.
The terms Nanobody® and Nanobodies® are trademarks of Ablynx, a Sanofi company.
About Sonelokimab Sonelokimab (M1095) is an investigational ~40 kDa humanized Nanobody® consisting of three VHHs covalently linked by flexible glycine-serine spacers. With two domains, sonelokimab selectively binds with high affinity to IL-17A and IL-17F, thereby inhibiting the IL-17A/A, IL-17A/F, and IL-17F/F dimers. A third central domain binds to human albumin, facilitating further enrichment of sonelokimab at sites of inflammatory edema.
Sonelokimab is being assessed in two lead indications, hidradenitis suppurativa (HS) and psoriatic arthritis (PsA), and the Company is pursuing other indications in dermatology and rheumatology, including adolescent HS, palmoplantar pustulosis (PPP) and axial spondyloarthritis (axSpA).
For adults with HS, sonelokimab is being assessed in two identical Phase 3 trials, the VELA-1 and VELA-2 trials, using the higher clinical response level of HS Clinical Response (HiSCR) 75 as the primary endpoint, which defines a response as an at least 75% reduction in abscess and inflammatory nodule count, with no increase from baseline in abscess or draining tunnel count. In September 2025, the primary endpoint data from the VELA-1 and VELA-2 clinical trials were announced. In the combined VELA program, patients treated with sonelokimab experienced a clinically meaningful and statistically significant improvement across all primary and key secondary endpoints using both pre-specified strategies (p
